|
||
Itravil Uses |
||
for the treatment of people with a body mass index (BMI) less than or greater than 30 kg / m2 and who have not responded to a diet. Especially for those patients with diabetes, heart disease and hypertension.
Obesity
Adult: 30 mg bid.
Itravil not be administered concomitantly with:-- Antidepressants or MAO inhibitors (MAOIs).-- Guanethidine or its derivatives, since both share the same active site of action. Guanethidine and its derivatives could be displaced by deleting its antihypertensive effect.-- Phenylethylamine derivatives, appetite suppressants, and tricyclic antidepressants may potentiate the effects of the latter.-- Sympathomimetic agents and general anesthetics, can cause arrhythmias. It should be administered 14 days after stopping treatment with an MAOI, because it may cause hypertensive crisis.
Have been reported cases of pulmonary arterial hypertension, severe disease with life threatening risks. One symptom is: the occurrence or aggravation of exertional dyspnea in this case should be discontinued treatment immediately.
Central nervous system: Itravil Prolonged use may develop drug tolerance, dependence and withdrawal. The most common adverse reactions are: psychotic reactions, or psychosis, depression, nervousness, agitation, sleep disturbances and dizziness. Seizures have occasionally been reported, headache.
Cardiovascular effects: Most often include tachycardia, palpitations, hypertension and chest pain. Have been rarely reported cardiovascular or cerebrovascular accidents, particularly stroke, angina, myocardial infarction, heart failure and cardiac arrest in patients treated with anorectic agents.
Gastrointestinal effects: Dry mouth and constipation.
Effect on Urinary Tract Dysuria, urinary retention.
Not be given to patients hypersensitive to the components of the formula. Not be given to elderly people or children under 12 years. Not be given to patients with:-- Pulmonary arterial hypertension or severe.-- Psychiatric disorders, including anorexia nervosa and depression.-- Advanced arteriosclerosis.-- Hyperthyroidism.-- Prostatic hypertrophy or obstructive disease of the urinary tract.-- Antidepressants or monoamine oxidase inhibitors (MAOIs).-- History of cardiovascular or cerebrovascular disease.-- Background or who are prone to drug and / or alcohol.
Clobenzorex in Mexico.
Clobenzorex hydrochloride in Mexico.
Unit description / dosage (Manufacturer) | Price, USD |
Capsule; Oral; Clobenzorex Hydrochloride 30 mg | |
List of Itravil substitutes (brand and generic names): | |
Asenlix (Mexico) | |
Capsule; Oral; Clobenzorex Hydrochloride 30 mg (Aventis) | |
Clobenzorex (Antigua & Barbuda, Aruba, Bahamas, Barbados, Bermuda, Cayman Islands, Guyana, Jamaica, Saint Lucia, Saint Vincent & The Grenadines, Trinidad & Tobago) | |
Clobenzorex Hcl | |
Clobenzorex hydrochloride | |
Dinintel (Antigua & Barbuda, Aruba, Bahamas, Barbados, Bermuda, Cayman Islands, Guyana, Haiti, Jamaica, Netherlands Antilles, Saint Lucia, Saint Vincent & The Grenadines, Trinidad & Tobago) | |
Ezbencx (Mexico) | |
Finedal (Spain) | |
Itravil Ap (Mexico) | |
Itravil IFA | |
Capsule; Oral; Clobenzorex Hydrochloride 30 mg | |
Itravil-Ifa (Mexico) | |
Obeclox (Costa Rica, Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, Panama) | |
Capsule; Oral; Clobenzorex Hydrochloride 30 mg (Medix) | |
sponsored
| |
Redicres (Mexico) |
Users | % | ||
---|---|---|---|
Expensive | 1 | 100.0% |
Users | % | ||
---|---|---|---|
> 3 month | 3 | 75.0% | |
1 day | 1 | 25.0% |
Users | % | ||
---|---|---|---|
16-29 | 7 | 31.8% | |
30-45 | 7 | 31.8% | |
46-60 | 5 | 22.7% | |
> 60 | 3 | 13.6% |
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|